4-Tert-butyl-2-methylthieno[2,3-d]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 4-Tert-butyl-2-methylthieno[2,3-d]pyrimidine
• 英文别名: 4-tert-butyl-2-methylthieno[2,3-d]pyrimidine
• 化学式: C₁₁H₁₄N₂S
• 分子量: 206.31
• InChiKey: PLSCSQYQYLVPHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION
  申请人：Infinity Pharmaceuticals, Inc.

  公开号：US20140088099A1

  公开（公告）日：2014-03-27

  Chemical compounds that modulate kinase activity, including PI3 kinase activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.

  本文描述了调节激酶活性的化合物，包括PI3激酶活性的化合物，以及与激酶活性相关的疾病和病况的化学化合物、制药组合物和治疗方法，其中包括P13激酶活性。
• Biaryl kinase inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10246469B2

  公开（公告）日：2019-04-02

  The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.

  本公开涉及可抑制 AAK1（适配体相关激酶 1）的式（I）双芳基化合物、包含此类化合物的组合物及其用于治疗疼痛、阿尔茨海默病、帕金森病和精神分裂症等疾病的用途。
• BIARYL KINASE INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20190040080A1

  公开（公告）日：2019-02-07

  The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.
• US9181221B2
  申请人：——

  公开号：US9181221B2

  公开（公告）日：2015-11-10